List With HCPCS Codes For Medicare Demonstration Projects

The HCPCS codes for Medicare Demonstration Projects G9013-G9140 cover a range of services related to various types of cancer, smoking cessation counseling, and extended stays in frontier clinics. These codes are used specifically for Medicare-approved demonstration projects.

1. HCPCS Code G9013

HCPCS G9013 describes the basic bundle of services for patients with end-stage renal disease (ESRD) participating in a Medicare demonstration project.

2. HCPCS Code G9014

HCPCS G9014 covers an expanded bundle of services for ESRD patients in a Medicare demonstration project, including venous access and related services.

3. HCPCS Code G9016

HCPCS G9016 is used for individual smoking cessation counseling sessions lasting 6-10 minutes, either in the absence of or in addition to other evaluation and management services, as part of a Medicare demonstration project.

4. HCPCS Code G9050

HCPCS G9050 is specific to a Medicare-approved demonstration project and is used for work-up, evaluation, or staging at the time of cancer diagnosis or recurrence in oncology patients.

5. HCPCS Code G9051

HCPCS G9051 is used in a Medicare-approved demonstration project for treatment decision-making, discussion of treatment options, and supervising/coordinating active cancer-directed therapy or managing consequences of cancer-directed therapy in oncology patients.

6. HCPCS Code G9052

HCPCS G9052 is used in a Medicare-approved demonstration project for surveillance of disease recurrence in oncology patients who have completed definitive cancer-directed therapy and currently show no evidence of recurrent disease.

7. HCPCS Code G9053

HCPCS G9053 is used in a Medicare-approved demonstration project for expectant management of oncology patients with evidence of cancer but no current administration or arrangement of cancer-directed therapy, with the possibility of considering cancer-directed therapy in the future.

8. HCPCS Code G9054

HCPCS G9054 is used in a Medicare-approved demonstration project for the supervision, coordination, and management of care for oncology patients with terminal cancer or other medical illnesses preventing further cancer treatment, including symptom management, end-of-life care planning, and palliative therapies.

9. HCPCS Code G9055

HCPCS G9055 is an unspecified service code used in a Medicare-approved demonstration project for oncology patients when the service provided does not fall under any other specific code.

10. HCPCS Code G9056

HCPCS G9056 is used in a Medicare-approved demonstration project to indicate that the management of oncology patients adheres to practice guidelines.

11. HCPCS Code G9057

HCPCS G9057 is used in a Medicare-approved demonstration project to indicate that the management of oncology patients differs from practice guidelines due to patient enrollment in an institutional review board approved clinical trial.

12. HCPCS Code G9058

HCPCS G9058 is used in a Medicare-approved demonstration project to indicate that the management of oncology patients differs from practice guidelines because the treating physician disagrees with guideline recommendations.

13. HCPCS Code G9059

HCPCS G9059 is used in a Medicare-approved demonstration project to indicate that the management of oncology patients differs from practice guidelines because the patient has opted for alternative treatment or management, including no treatment, after being offered treatment consistent with guidelines.

14. HCPCS Code G9060

HCPCS G9060 is used in a Medicare-approved demonstration project to indicate that the management of oncology patients differs from practice guidelines due to patient comorbid illness or performance status not factored into the guidelines.

15. HCPCS Code G9061

HCPCS G9061 is used in a Medicare-approved demonstration project to indicate that the patient’s condition is not addressed by available practice guidelines.

16. HCPCS Code G9062

HCPCS G9062 is used in a Medicare-approved demonstration project to indicate that the management of oncology patients differs from practice guidelines for reasons not listed.

17. HCPCS Code G9063

HCPCS G9063 is used in a Medicare-approved demonstration project to indicate the disease status of non-small cell lung cancer patients initially established as Stage I with no evidence of disease progression, recurrence, or metastases.

18. HCPCS Code G9064

HCPCS G9064 is used in a Medicare-approved demonstration project to indicate the disease status of non-small cell lung cancer patients initially established as Stage II with no evidence of disease progression, recurrence, or metastases.

19. HCPCS Code G9065

HCPCS G9065 is used in a Medicare-approved demonstration project to indicate the disease status of non-small cell lung cancer patients initially established as Stage III A with no evidence of disease progression, recurrence, or metastases.

20. HCPCS Code G9066

HCPCS G9066 is used in a Medicare-approved demonstration project to indicate the disease status of non-small cell lung cancer patients diagnosed with Stage III B-IV, metastatic, locally recurrent, or progressive disease.

21. HCPCS Code G9067

HCPCS G9067 is used in a Medicare-approved demonstration project to indicate the disease status of non-small cell lung cancer patients with unknown extent of disease, staging in progress, or not listed.

22. HCPCS Code G9068

HCPCS G9068 is used in a Medicare-approved demonstration project to indicate the disease status of small cell and combined small cell/non-small cell lung cancer patients initially established as limited with no evidence of disease progression, recurrence, or metastases.

23. HCPCS Code G9069

HCPCS G9069 is used in a Medicare-approved demonstration project to indicate the disease status of small cell and combined small cell/non-small cell lung cancer patients diagnosed with extensive Stage disease, metastatic, locally recurrent, or progressive.

24. HCPCS Code G9070

HCPCS G9070 is used in a Medicare-approved demonstration project to indicate the disease status of small cell and combined small cell/non-small cell lung cancer patients with unknown extent of disease, staging in progress, or not listed.

25. HCPCS Code G9071

HCPCS G9071 is used in a Medicare-approved demonstration project to indicate the disease status of invasive female breast cancer patients with Stage I or Stage IIA-IIB, ER and/or PR positive, and no evidence of disease progression, recurrence, or metastases.

26. HCPCS Code G9072

HCPCS G9072 is used in a Medicare-approved demonstration project to indicate the disease status of invasive female breast cancer patients with Stage I or Stage IIA-IIB, ER and PR negative, and no evidence of disease progression, recurrence, or metastases.

27. HCPCS Code G9073

HCPCS G9073 is used in a Medicare-approved demonstration project to indicate the disease status of invasive female breast cancer patients with Stage IIIA-IIIB, not T3, N1, M0, ER and/or PR positive, and no evidence of disease progression, recurrence, or metastases.

28. HCPCS Code G9074

HCPCS G9074 is used in a Medicare-approved demonstration project to indicate the disease status of invasive female breast cancer patients with Stage IIIA-IIIB, not T3, N1, M0, ER and PR negative, and no evidence of disease progression, recurrence, or metastases.

29. HCPCS Code G9075

HCPCS G9075 is used in a Medicare-approved demonstration project to indicate the disease status of invasive female breast cancer patients with M1 at diagnosis, metastatic, locally recurrent, or progressive disease.

30. HCPCS Code G9077

HCPCS G9077 is used in a Medicare-approved demonstration project to indicate the disease status of prostate cancer patients with adenocarcinoma as the predominant cell type, T1-T3C, Gleason 2-7, and PSA ≤ 20 at diagnosis, and no evidence of disease progression, recurrence, or metastases.

31. HCPCS Code G9078

HCPCS G9078 is used in a Medicare-approved demonstration project to indicate the disease status of prostate cancer patients with adenocarcinoma as the predominant cell type, T2 or T3A, Gleason 8-10, or PSA > 20 at diagnosis, and no evidence of disease progression, recurrence, or metastases.

32. HCPCS Code G9079

HCPCS G9079 is used in a Medicare-approved demonstration project to indicate the disease status of prostate cancer patients with adenocarcinoma as the predominant cell type, T3B-T4, any N, or any T, N1 at diagnosis, and no evidence of disease progression, recurrence, or metastases.

33. HCPCS Code G9080

HCPCS G9080 is used in a Medicare-approved demonstration project to indicate the disease status of prostate cancer patients with adenocarcinoma after initial treatment, with rising PSA or failure of PSA decline.

34. HCPCS Code G9083

HCPCS G9083 is used in a Medicare-approved demonstration project to indicate the disease status of prostate cancer patients with adenocarcinoma, with extent of disease unknown, staging in progress, or not listed.

35. HCPCS Code G9084

HCPCS G9084 is used in a Medicare-approved demonstration project to indicate the disease status of colon cancer patients with invasive cancer, adenocarcinoma as the predominant cell type, initially established as T1-3, N0, M0, and no evidence of disease progression, recurrence, or metastases.

36. HCPCS Code G9085

HCPCS G9085 is used in a Medicare-approved demonstration project to indicate the disease status of colon cancer patients with invasive cancer, adenocarcinoma as the predominant cell type, initially established as T4, N0, M0, and no evidence of disease progression, recurrence, or metastases.

37. HCPCS Code G9086

HCPCS G9086 is used in a Medicare-approved demonstration project to indicate the disease status of colon cancer patients with invasive cancer, adenocarcinoma as the predominant cell type, initially established as T1-4, N1-2, M0, and no evidence of disease progression, recurrence, or metastases.

38. HCPCS Code G9087

HCPCS G9087 is used in a Medicare-approved demonstration project to indicate the disease status of colon cancer patients with invasive cancer, adenocarcinoma as the predominant cell type, M1 at diagnosis, metastatic, locally recurrent, or progressive disease, with current clinical, radiologic, or biochemical evidence of disease.

39. HCPCS Code G9088

HCPCS G9088 is used in a Medicare-approved demonstration project to indicate the disease status of colon cancer patients with invasive cancer, adenocarcinoma as the predominant cell type, M1 at diagnosis, metastatic, locally recurrent, or progressive disease, without current clinical, radiologic, or biochemical evidence of disease.

40. HCPCS Code G9089

HCPCS G9089 is used in a Medicare-approved demonstration project to indicate the disease status of colon cancer patients with invasive cancer, adenocarcinoma as the predominant cell type, with extent of disease unknown, staging in progress, or not listed.

41. HCPCS Code G9090

HCPCS G9090 is used in a Medicare-approved demonstration project to indicate the disease status of rectal cancer patients with invasive cancer, adenocarcinoma as the predominant cell type, initially established as T1-2, N0, M0, and no evidence of disease progression, recurrence, or metastases.

42. HCPCS Code G9091

HCPCS G9091 is used in a Medicare-approved demonstration project to indicate the disease status of rectal cancer patients with invasive cancer, adenocarcinoma as the predominant cell type, initially established as T3, N0, M0, and no evidence of disease progression, recurrence, or metastases.

43. HCPCS Code G9092

HCPCS G9092 is used in a Medicare-approved demonstration project to indicate the disease status of rectal cancer patients with invasive cancer, adenocarcinoma as the predominant cell type, initially established as T1-3, N1-2, M0, and no evidence of disease progression, recurrence, or metastases.

44. HCPCS Code G9093

HCPCS G9093 is used in a Medicare-approved demonstration project to indicate the disease status of rectal cancer patients with invasive cancer, adenocarcinoma as the predominant cell type, initially established as T4, any N, M0, and no evidence of disease progression, recurrence, or metastases.

45. HCPCS Code G9094

HCPCS G9094 is used in a Medicare-approved demonstration project to indicate the disease status of rectal cancer patients with invasive cancer, adenocarcinoma as the predominant cell type, M1 at diagnosis, metastatic, locally recurrent, or progressive disease.

46. HCPCS Code G9095

HCPCS G9095 is used in a Medicare-approved demonstration project to indicate the disease status of rectal cancer patients with invasive cancer, adenocarcinoma as the predominant cell type, with extent of disease unknown, staging in progress, or not listed.

47. HCPCS Code G9096

HCPCS G9096 is used in a Medicare-approved demonstration project to indicate the disease status of esophageal cancer patients with adenocarcinoma or squamous cell carcinoma as the predominant cell type, initially established as T1-T3, N0-N1 or NX, and no evidence of disease progression, recurrence, or metastases.

48. HCPCS Code G9097

HCPCS G9097 is used in a Medicare-approved demonstration project to indicate the disease status of esophageal cancer patients with adenocarcinoma or squamous cell carcinoma as the predominant cell type, initially established as T4, any N, M0, and no evidence of disease progression, recurrence, or metastases.

49. HCPCS Code G9098

HCPCS G9098 is used in a Medicare-approved demonstration project to indicate the disease status of esophageal cancer patients with adenocarcinoma or squamous cell carcinoma as the predominant cell type, M1 at diagnosis, metastatic, locally recurrent, or progressive disease.

50. HCPCS Code G9099

HCPCS G9099 is used in a Medicare-approved demonstration project to indicate the disease status of esophageal cancer patients with adenocarcinoma or squamous cell carcinoma as the predominant cell type, with extent of disease unknown, staging in progress, or not listed.

51. HCPCS Code G9100

HCPCS G9100 is used in a Medicare-approved demonstration project to indicate the disease status of gastric cancer patients with adenocarcinoma as the predominant cell type, post R0 resection (with or without neoadjuvant therapy), and no evidence of disease recurrence, progression, or metastases.

52. HCPCS Code G9101

HCPCS G9101 is used in a Medicare-approved demonstration project to indicate the disease status of gastric cancer patients with adenocarcinoma as the predominant cell type, post R1 or R2 resection (with or without neoadjuvant therapy), and no evidence of disease progression or metastases.

53. HCPCS Code G9102

HCPCS G9102 is used in a Medicare-approved demonstration project to indicate the disease status of gastric cancer patients with adenocarcinoma as the predominant cell type, clinical or pathologic M0, and unresectable disease with no evidence of disease progression or metastases.

54. HCPCS Code G9103

HCPCS G9103 is used in a Medicare-approved demonstration project to indicate the disease status of gastric cancer patients with adenocarcinoma as the predominant cell type, clinical or pathologic M1 at diagnosis, metastatic, locally recurrent, or progressive disease.

55. HCPCS Code G9104

HCPCS G9104 is used in a Medicare-approved demonstration project to indicate the disease status of gastric cancer patients with adenocarcinoma as the predominant cell type, with extent of disease unknown, staging in progress, or not listed.

56. HCPCS Code G9105

HCPCS G9105 is used in a Medicare-approved demonstration project to indicate the disease status of pancreatic cancer patients with adenocarcinoma as the predominant cell type, post R0 resection, and no evidence of disease progression, recurrence, or metastases.

57. HCPCS Code G9106

HCPCS G9106 is used in a Medicare-approved demonstration project to indicate the disease status of pancreatic cancer patients with adenocarcinoma, post R1 or R2 resection, and no evidence of disease progression or metastases.

58. HCPCS Code G9107

HCPCS G9107 is used in a Medicare-approved demonstration project to indicate the disease status of pancreatic cancer patients with adenocarcinoma, unresectable at diagnosis, M1 at diagnosis, metastatic, locally recurrent, or progressive disease.

59. HCPCS Code G9108

HCPCS G9108 is used in a Medicare-approved demonstration project to indicate the disease status of pancreatic cancer patients with adenocarcinoma, with extent of disease unknown, staging in progress, or not listed.

60. HCPCS Code G9109

HCPCS G9109 is used in a Medicare-approved demonstration project to indicate the disease status of head and neck cancer patients with squamous cell as the predominant cell type, initially established as T1-T2 and N0, M0, and no evidence of disease progression, recurrence, or metastases.

61. HCPCS Code G9110

HCPCS G9110 is used in a Medicare-approved demonstration project to indicate the disease status of head and neck cancer patients with squamous cell as the predominant cell type, initially established as T3-4 and/or N1-3, M0, and no evidence of disease progression, recurrence, or metastases.

62. HCPCS Code G9111

HCPCS G9111 is used in a Medicare-approved demonstration project to indicate the disease status of head and neck cancer patients with squamous cell as the predominant cell type, M1 at diagnosis, metastatic, locally recurrent, or progressive disease.

63. HCPCS Code G9112

HCPCS G9112 is used in a Medicare-approved demonstration project to indicate the disease status of head and neck cancer patients with squamous cell as the predominant cell type, with extent of disease unknown, staging in progress, or not listed.

64. HCPCS Code G9113

HCPCS G9113 is used in a Medicare-approved demonstration project to indicate the disease status of ovarian cancer patients with epithelial cancer, pathologic Stage IA-B (Grade 1), and no evidence of disease progression, recurrence, or metastases.

65. HCPCS Code G9114

HCPCS G9114 is used in a Medicare-approved demonstration project to indicate the disease status of ovarian cancer patients with epithelial cancer, pathologic Stage IA-B (Grade 2-3), or Stage IC (all grades), or Stage II, and no evidence of disease progression, recurrence, or metastases.

66. HCPCS Code G9115

HCPCS G9115 is used in a Medicare-approved demonstration project to indicate the disease status of ovarian cancer patients with epithelial cancer, pathologic Stage III-IV, and no evidence of disease progression, recurrence, or metastases.

67. HCPCS Code G9116

HCPCS G9116 is used in a Medicare-approved demonstration project to indicate the disease status of ovarian cancer patients with epithelial cancer and evidence of disease progression, recurrence, and/or platinum resistance.

68. HCPCS Code G9117

HCPCS G9117 is used in a Medicare-approved demonstration project to indicate the disease status of ovarian cancer patients with epithelial cancer, with extent of disease unknown, staging in progress, or not listed.

69. HCPCS Code G9123

HCPCS G9123 is used in a Medicare-approved demonstration project to indicate the disease status of chronic myelogenous leukemia patients with Philadelphia chromosome positive and/or BCR-ABL positive, in the chronic phase without hematologic, cytogenetic, or molecular remission.

70. HCPCS Code G9124

HCPCS G9124 is used in a Medicare-approved demonstration project to indicate the disease status of chronic myelogenous leukemia patients with Philadelphia chromosome positive and/or BCR-ABL positive, in the accelerated phase without hematologic, cytogenetic, or molecular remission.

71. HCPCS Code G9125

HCPCS G9125 is used in a Medicare-approved demonstration project to indicate the disease status of chronic myelogenous leukemia patients with Philadelphia chromosome positive and/or BCR-ABL positive, in the blast phase without hematologic, cytogenetic, or molecular remission.

72. HCPCS Code G9126

HCPCS G9126 is used in a Medicare-approved demonstration project to indicate the disease status of chronic myelogenous leukemia patients with Philadelphia chromosome positive and/or BCR-ABL positive, in hematologic, cytogenetic, or molecular remission.

73. HCPCS Code G9128

HCPCS G9128 is used in a Medicare-approved demonstration project to indicate the disease status of multiple myeloma patients with systemic disease, in the smoldering stage (Stage I).

74. HCPCS Code G9129

HCPCS G9129 is used in a Medicare-approved demonstration project to indicate the disease status of multiple myeloma patients with systemic disease, Stage II or higher.

75. HCPCS Code G9130

HCPCS G9130 is used in a Medicare-approved demonstration project to indicate the disease status of multiple myeloma patients with systemic disease, with extent of disease unknown, staging in progress, or not listed.

76. HCPCS Code G9131

HCPCS G9131 is used in a Medicare-approved demonstration project to indicate the disease status of invasive female breast cancer patients with extent of disease unknown, staging in progress, or not listed.

77. HCPCS Code G9132

HCPCS G9132 is used in a Medicare-approved demonstration project to indicate the disease status of prostate cancer patients with adenocarcinoma, hormone-refractory/androgen-independent, clinical metastases.

78. HCPCS Code G9133

HCPCS G9133 is used in a Medicare-approved demonstration project to indicate the disease status of prostate cancer patients with adenocarcinoma, hormone-responsive, clinical metastases or M1 at diagnosis.

79. HCPCS Code G9134

HCPCS G9134 is used in a Medicare-approved demonstration project to indicate the disease status of non-Hodgkin’s lymphoma patients with any cellular classification, Stage I or II at diagnosis, not relapsed or refractory.

80. HCPCS Code G9135

HCPCS G9135 is used in a Medicare-approved demonstration project to indicate the disease status of non-Hodgkin’s lymphoma patients with any cellular classification, Stage III or IV, not relapsed or refractory.

81. HCPCS Code G9136

HCPCS G9136 is used in a Medicare-approved demonstration project to indicate the disease status of non-Hodgkin’s lymphoma patients with a transformed cellular diagnosis to a second cellular classification.

82. HCPCS Code G9137

HCPCS G9137 is used in a Medicare-approved demonstration project to indicate the disease status of non-Hodgkin’s lymphoma patients with any cellular classification, relapsed or refractory disease.

83. HCPCS Code G9138

HCPCS G9138 is used in a Medicare-approved demonstration project to indicate the disease status of non-Hodgkin’s lymphoma patients with any cellular classification, for diagnostic evaluation, stage not determined, evaluation of possible relapse or non-response to therapy, or not listed.

84. HCPCS Code G9139

HCPCS G9139 is used in a Medicare-approved demonstration project to indicate the disease status of chronic myelogenous leukemia patients with Philadelphia chromosome positive and/or BCR-ABL positive, with extent of disease unknown, staging in progress, or not listed.

85. HCPCS Code G9140

HCPCS G9140 is a terminated code that was used in a Medicare-approved demonstration project to indicate an extended stay in a frontier clinic, with specific criteria for the duration of the stay and payment structure.